Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Indications/Uses
Multiple myeloma.
|
|
Dosage/Direction for Use
Adult: IV 1.3 mg/m2 as bolus on days 1, 4, 8 and 11 of a 21-day cycle, followed by a 10-day rest period (days 12-21). Ensure at least 72-hr gap between consecutive doses.
|
|
Contraindications
Hypersensitivity. Child. Pregnancy and lactation.
|
|
Special Precautions
Hepatic or renal impairment; history of syncope, orthostatic hypotension; dehydration. Impairs ability to drive or operate machinery. Monitor for symptoms of peripheral neuropathy. Monitor closely the blood glucose levels in patients receiving oral antidiabetic agents.
|
|
Adverse Reactions
Asthenic conditions; pyrexia; GI disturbances, anorexia; dehydration; peripheral neuropathy; thrombocytopenia, neutropenia, anaemia; hypotension; cardiac disorders; bone and body pain; cough, dyspnoea; rash, oedema; hypersensitivity reactions; painful or difficult urination.
Potentially Fatal: Pneumonia, pyrexia, diarrhoea, vomiting, dehydration and nausea. |
|
Drug Interactions
Concurrent use of amiodarone, antivirals, isoniazid, nitrofurantoin, statins may increase the chance of peripheral neuropathy.
Concurrent use of antihypertensives increases the chance of hypotension.
|
|
CIMS Class
|
|
ATC Classification
L01XX32 - bortezomib ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.
|
